Personalised multi-drug therapy guided by tumour DNA improves outcomes
Precision oncology has traditionally focused on matching single drugs to single molecular alterations. However, most…
Precision oncology has traditionally focused on matching single drugs to single molecular alterations. However, most…
Recognising the sight of blood in urine, the most common first sign of bladder cancer,…
New data presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) highlight continued momentum…
New research from a regional Australian cancer centre has assessed the practical utility of molecular…
New observational evidence from a large US cohort suggests that, for men with metastatic castration-resistant…
Emerging evidence from a longitudinal cohort study published in JAMA Network Open suggests that exposure…
New data from a phase 3 randomised clinical trial published in JAMA Network Open has…
Recreational physical activity may be associated with breast tissue composition and biomarkers of stress in…
Ipsen Australia welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Cabometyx® (cabozantinib) for the treatment…
Cancer immunotherapy involves harnessing the body’s immune system to fight tumours; however, delivering treatments effectively…